SCHEMBL753707

SCHEMBL753707

O=C(Oc1ccccc1)n1cc[c]n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
CYP3A4 P08684 7/20 0.41
SMN1; SMN2 Q16637 7/20 0.41
TSHR P16473 5/20 0.41
MAPK1 P28482 4/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2C19 P33261 3/20 0.41
MGLL Q99685 1/20 0.41
ALDH1A1 P00352 6/20 0.41
CYP2C9 P11712 5/20 0.41
HSD17B10 Q99714 2/20 0.41
USP2 O75604 2/20 0.41
HPGD P15428 1/20 0.41
BCHE P06276 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25412576 0.72 ELANE (0.46) GAAALDH1A1BCHENPC1RAB9A
SCHEMBL11030328 0.71 GAA (0.44) GAACYP3A4SMN1; SMN2TSHRMAPK1
SCHEMBL6631580 0.69
SCHEMBL11882343 0.69 MGLL (0.72) GAACYP3A4SMN1; SMN2TSHRMAPK1
SCHEMBL27342875 0.69 BCHE (0.49) GAACYP3A4SMN1; SMN2TSHRMAPK1
SCHEMBL12016609 0.68 MGLL (0.46) GAACYP3A4SMN1; SMN2TSHRMAPK1
SCHEMBL1502065 0.68 KMT2A (0.50) GAASMN1; SMN2TSHRMAPK1MGLL
SCHEMBL970890 0.67 USP2 (0.37) SMN1; SMN2USP2HPGDBCHEKMT2A
SCHEMBL11027751 0.67 ASAH1 (0.46) GAATSHRALDH1A1HPGDBCHE
SCHEMBL32666116 0.67 MAPT (0.43) GAASMN1; SMN2TSHRMAPK1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD GAA 684/4885CYP3A4 1828/4885SMN1; SMN2 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.